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There remains a clear need for effective tumor cell purging in
autologous stem cell transplantation (ASCT) where residual
malignant cells within the autograft contribute to disease
relapse. Here we propose the use of a novel Fas agonist with
potent pro-apoptotic activity, termed MegaFasL, as an effective
ex-vivo purging agent. MegaFasL selectively kills hematologi-
cal cancer cells from lymphomas and leukemias and prevents
tumor development at concentrations that do not reduce the
functional capacity of human hematopoietic stem/progenitor
cells both in in vitro and in in vivo transplantation models.
These findings highlight the potential use of MegaFasL as an
ex-vivo purging agent in ASCT.
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Introduction
Autologous stem cell transplantation (ASCT) has become the
treatment of choice for an increasing number of selected
patients with hematological malignancies. In ASCT, hemato-
poietic progenitor cells (HPC) are harvested from the patient
before high-dose chemotherapy administered to the patient. The
HPC graft is subsequently re-infused to the patient, rescuing him
from hematopoietic toxicity linked to high-dose chemotherapy
administration. A major drawback of ASCT is the presence of
residual malignant cells within the graft re-infused to the patient.
This complication has been correlated with disease relapse,1–5
but can be circumvented by ex-vivo purging of the graft to
remove cancer cells while preserving HPC. In recent years,
several technologies have been employed to purge cancerous
cells from ASCT,6 including positive selection for progenitor
cells,2,7,8 in vitro expansion of hematopoietic cells,9 depletion
of tumor cells,10,11 photodynamic purging processes,12,13
genetic modification of tumor cells14,15 and pulsed electric-
field cell selection.16,17 These methods are more or less weighty
and variably efficient at eliminating cancer cells from the
autograft in conditions that do not affect the hematopoietic
activity of the autograft. This warrants the development of
alternative simple methods to reduce or eliminate cancer cell
contamination from grafts during ASCT.
In this context, we developed a novel soluble hexameric
recombinant form of FasL, termed MegaFasL, which induces
high levels of caspase-dependent apoptosis in vitro upon
binding to cell surface Fas receptors.18 Indeed, Fas is expressed
on almost all human tumor cells19 including hematological
cancer cells. Interestingly, Fas is expressed at lower levels on
some human acute leukemia progenitor cells,20 making
attractive the use of a potent Fas agonist optimized for inducing
cell death and able to fully eradicate hematopoietic cancers. We
hypothesized that human HPC, regardless of their origin, would
be resistant to MegaFasL-induced cell death as previously
reported for other Fas-agonists21,22 at concentrations that would
eliminate such cancer cells.
Our study indicates that MegaFasL selectively kills hemato-
logical cancer cells and prevents tumor development at
concentrations that do not reduce the functional capacity of
human hematopoietic stem/progenitor cells both in an in vitro
and in an in vivo transplantation model. These findings highlight
the potential use of MegaFasL as an ex-vivo purging agent in
ASCT.
Materials and methods
Reagent and monoclonal antibodies
MegaFasL was produced in our laboratories under current good
manufacturer practice, resuspended in phosphate-buffered
saline, and stored at 20 1C in aliquots. Such compound had
a stable activity for at least 1 year. Information on the
monoclonal antibodies and reagents used is summarized in
Supplementary Table 1.
Cell origins, culture and analysis conditions
Human CD34þ cells from cord blood (CB), mobilized
peripheral blood (mPB) or bone marrow (BM) were obtained
unpurified (mPB) or already purified (CB, mPB, BM) from either
AllCells, LLC (San Mateo, CA, USA), or purified using an anti-
CD34 magnetic bead column (Miltenyi, Bergisch GladBach,
Germany) from CB collected at the Obstetric Department of the
CHUV after consent obtained from mothers. Aliquots of primary
cells (purity 480%) from consenting patients with acute
myeloid leukemia (AML 1: M2 subtype, AML 2: M3 subtype),
multiple myeloma (MM, IgA-l), marginal zone lymphoma and
follicular lymphoma were collected and frozen in medium
containing 10% dimethyl sulfoxide. The procedures have been
accepted by the local ethics committee of our hospital.
Information on cell lines used in the present manuscript is
provided in Supplementary Table 2. Aliquots of cryopreserved
CD34þ cells were thawed and washed twice, and theirReceived 3 October 2011; accepted 10 October 2011
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viabilities were 88±6% (by Trypan blue dye exclusion) and
contained 95±2% CD34þ cells by fluorescence-activated cell
sorting (FACS) analysis of immunostained cells. HPC, malignant
cells from patients and cell lines incubated with or without
MegaFasL were culture as previously described.18 Apoptosis
was monitored using annexin-V and 7-aminoactinomycin D
stainings as described by the manufacturer. The analysis was
carried out using a five-color flow cytometer (Beckman Coulter
Cytomics FC500, Beckman Coulter, Nyon, Switzerland).
Colony-forming cells (CFU) assay
CD34þ cells incubated with or without MegaFasL for 5 h were
evaluated for their capacity to generate granulocyte/macro-
phage (CFU-G/M), burst-forming units-erythroid colonies and
multi-lineage (CFU-Mix) colonies, by plating 0.5 to 1 103
CD34þ cells (from either mPB or CB) in 1-ml methylcellulose
medium supplemented with human growth factors (Methocult
GFþ H4435, StemCell Technologies Inc., Vancouver, BC, Canada).
Colonies were scored under an inverted microscope after 2 weeks
at 37 1C, in a humidified atmosphere at 5% CO2. CFU assays were
similarly performed on 105 BM cells from transplanted nonobese
diabetes/severe combined immunodeficiency (NOD/SCID) mice.
Long-term culture-initiating cell assay
Bulk long-term culture-initiating cell assays were performed
according to the technique described elsewhere.23,24 Bone
marrow stromal cells (M2-10B4 cell line) were cultured in RPMI
medium, harvested and irradiated (80 Gy). Subsequently,
adherent cells (3 105per ml per well) were replated in 24-
well plates and cultured in 1-ml Myelocult medium (StemCell
Technologies Inc.) containing 1 106 M hydrocortisone. After
24 h, the stromal layers were added with 2 104 CD34þ cells
from mPB or CB per well, previously incubated in the presence
or absence of MegaFasL for 5 h. Cells were cultured for 6 weeks
with weekly half-medium changes then washed, counted and
plated for colony scoring as described above.
Transplantation of human cells in NOD/SCID mice and
xenochimeric mouse analyses
NOD/LtSz-Prkdcscid/Prkdcscid mice were purchased from Iffa
Credo (L’Arbresle, France), bred and maintained in micro-
isolator cages within a specific pathogen-free room in the
animal facility of the University Hospital of Lausanne. All
animals were handled according to the institutional regulations
after approval of the local animal ethics committee. Manipula-
tions were performed under a laminar flow hood under sterile
conditions. Mice to be transplanted were given 250-cGy total
body irradiation at 6 to 8 weeks of age from a 137Cesium 4000Ci
source (Robatel, Genas, France). Within 24 h of irradiation, the
mice were injected with either 2–4 106 CD34þ cells from
mPB or 5–7 105 CD34þ cells from CB. Alternatively, mice
received a mixture of 7 105 CD34þ cells from CB and 1 104
Raji cells, or with 1 104 Raji cells that had been incubated
with or without MegaFasL (at 50 and 200 ng/ml). In experiments
in which CD34þ cells were injected into mice, the engraftment
of the HPC and the multi-lineage reconstitution of human
hematopoietic cells were assessed 6 weeks after transplantation.
The transplanted mice were killed and BM cells were flushed
from both femurs and tibias with phosphate-buffered saline
containing 1% bovine serum albumin. Cells were then either
analyzed by FACS using human-specific antibodies, plated for
CFU assay, or processed for further DNA extraction.
Mice injected with Raji cells were followed daily for hind-leg
paralysis development, a robust sign of Raji tumor growth. Mice
with paresis were killed, and lymphoma presence evaluated by
FACS examination of BM. Mice given a mixture of CD34þ and
Raji cells without paresis were killed 6 weeks after the transplant
and analyzed as above.
Polymerase chain reactions
DNAs were extracted from xenochimeric mouse BM cells, and
from Raji cells diluted in NOD/SCID mouse BM cells at various
percentages, using Qiamp DNA blood mini Kit (Qiagen, Hilden,
Germany). DNAs were subjected to: (a) long-distance PCR for
the detection of t(8;14)(q24;q32) present in Burkitt’s lymphoma
Raji cells exactly as described,25 and (b) PCR for amplification of
human b-globin gene as described.26
Statistical analysis
The Kaplan–Meier method was used for the estimation of
differences in survival between different groups of mice (mice
receiving untreated cells (control) vs those given MegaFasL-
treated cells). Data are expressed as mean±s.d. unless noted.
Values between groups were compared using one-way analysis
of variance, non-parametric test with a GraphPad Prism 4.00
software (GraphPad Software Inc., San Diego, CA, USA). A
P-value less than 0.05 was considered as statistically significant.
Results
CD34þCD38low cells express low level of Fas and are
resistant to MegaFasL, whereas the latter efficiently
killing hematological cancer cells
As a first step, we determined Fas expressions on CD34þCD38low
cells from mPB, BM and CB, and on hematological malignant
cells. CD34þCD38low cells represent a sub-population of HPC
that are responsible for repopulating the hematopoietic system in
human HPC transplantation models,27 and were found to express
low level of cell surface Fas expression independently of their
origin (Figure 1a). In accordance with our previous studies, both
primary cells and cell lines from AML, MM and lymphoma
express variable, yet constantly high, levels of cell surface Fas
(Supplementary Figure 1).
We next evaluated the sensitivity of CD34þ cells to MegaFasL.
To investigate its cytotoxicity towards HPC, CD34þ cells from
various source (mPB, BM and CB) were incubated with MegaFasL
for 5 h, and apoptosis was determined by annexin and
7-aminoactinomycin D staining in early HPC (CD34þCD38low).
As shown in Figure 1b, CD34þCD38low cells from various
sources were resistant to killing mediated by MegaFasL, after
treament with MegafasL up to 200 ng/ml, with a threshold of less
than 12% HPC becoming apoptotic. This was confirmed on
unpurified mPB from three preparations (Supplementary
Figure 2). To extend the investigation into the effect of MegaFasL
on the hematological cancer cells tested in this study, we then
assessed the sensitivity of primary malignant cells and cell lines
from various hematological malignancies (AML, MM and
lymphoma). Cells were cultured for 5 h in presence or absence
of increasing concentrations of MegaFasL (0–200 ng/ml). As
shown in Supplementary Figure 3, in contrast to HPC, both
primary cells and cell lines from AML, MM and lymphoma were
highly sensitive to MegaFasL-induced apoptosis. Primary cells
from patients with AML and MM were the most sensitive, with
90–98% and 96% becoming apoptotic after treatement with
200 ng/ml. Two lymphoma primary cells displayed moderate
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sensitivity to MegaFasL with 65% apoptosis (follicular lympho-
ma) and 59% apoptosis (marginal zone lymphoma) seen at a
concentrentation of 200 ng/ml. All cancer cell lines tested in the
current study, except L363 were highly sensitive to MegaFasL,
with more than 80% apoptosis at 200 ng/ml. L363 showed an
intermediate sensitivity to MegaFasL, with 62% becoming
apoptotic after treatment with 200 ng/ml. These data also
confirm our previous observations on various types of hemato-
logical cancers from 12 patients and 9 different hematotopoietic
cancer cell lines.18 The variability in sensitivity to MegaFasL,
particularly in primary cells can be accounted for by variability
in Fas expression. Taken together, these data support that
MegaFasL kills most cancer cells while preserving HPC.
MegaFasL does not affect the clonogenic and in-vivo
repopulating capacities of HPC
To address this issue, we determined the clonogenic capacity of
purified HPC cells after treatment with MegaFasL in vitro.
CD34þ cells from mPB and CB were cultured for 5 h in
presence or absence of MegaFasL and then plated in the CFU
assays. Treatment with MegaFasL (up to 200 ng/ml) did not affect
the numbers of erythroid (burst-forming units-erythroid colo-
nies), granulocyte/macrophage (CFU-G/M) and mixed (CFU-
mix) colonies as compared with no treatment (Figure 2a). We
also investigated whether more primitive hematopoietic pro-
genitors than CFU would be affected by treatment with
MegaFasL using a bulk long-term culture-initiating cell assay.
We found that the potential of HPC to persist for 6 weeks and
subsequently differentiate into hematopoietic lineages was
similar when treated with up 200 ng/ml MegaFasL as compared
with untreated HPC, regardless of their origin (Figure 2b).
We next evaluated the effect of MegaFasL treatment on the
repopulating capacity of HPC (engraftment, persistence,
differentiation) transplanted in conditioned immune-deficient
mice.28–30 CD34þ cells from mPB or CB incubated with or
without MegaFasL were transplanted into irradiated NOD/SCID
mice and BM from xenochimeric animals were analyzed 6 weeks
thereafter. Human CD45þ cells were detected in the BM of all
NOD/SCID mice recipients 6 weeks after injection of CD34þ
cells. First, pre-treatment with MegaFasL had no effect on their
capacity to generate CD45þ cells (Figure 2c). Importantly,
viability or function of HPC from mPB, which have been exposed
to granulocyte colony-stimulating factor during the collection of
stem cells were not readily affected by MegaFasL treatment.
Second, FACS analysis using human-specific markers revealed
that MegaFasL-treated HPC from CB (Supplementary Table 1 and
Supplementary Figure 4) and mPB differentiated into erythroid
(glycophorin Aþ ), myeloid (CD33þ /CD13þ ), B-lymphoid
(CD19þ ) lineages and led to progenitors (CD34þ cells) at similar
percentages to those observed in untreated HPC. Third, the
capacity of xenochimeric BM cells to generate lineage-specific
CFU was quantitatively similar in MegaFasL-treated and control
groups (Figure 2d). FACS analysis confirmed the human origin of
CFU cells. These results strongly indicate that MegaFasL does not
affect the functional capacity of HPC to differentiate into the
expected lineages in vivo.
Taken together, the above results strongly suggest that
hematological malignant cells could be eliminated using
concentrations of MegaFasL that had little effect on the function
of HPC, highlighting a potential therapeutic window for the use
of MegaFasL as an ex-vivo purging agent in ASCT.
MegaFasL eradicates tumor cells, whereas sparing the
hematopoietic function of HPC, and prevents at long
term the tumor development in NOD/SCID model of
human Burkitt’s lymphoma
We developed a laboratory model of a proof of concept for
MegaFasL as an ex-vivo purging agent in ASCT. We used CB as
Figure 1 CD34þCD38low cells express low level of Fas and are resistant to MegaFasL. (a) Cell surface Fas expression on CD34þCD38low
cells determined by FACS using a fluorochrome-labelled antibody against human Fas (solid line). The numbers represent the fold increase
in mean fluorescence intensity compared with that of an isotypic control antibody (filled area). (b) CD34þ cells from mPB, BM or CB cells
were thawed and incubated with or without different concentrations of MegaFasL for 5 h, and apoptosis was evaluated by FACS using annexin-V
and 7-aminoactinomycin D dyes. Alternatively, CD34þ cells were similarly analyzed immediately after thawing cells (pre-incub). Annexin-Vþ
and 7-aminoactinomycin D cells represent early apoptotic cells (hatched bars) and annexin-Vþ and 7-aminoactinomycin Dþ cells represent late
apoptotic cells (solid black bars). Data are representative of three independent experiments.
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source for HPC in this model, because CD34þ cells from mPB
and CB are similarly resistant to MegaFasL (see above) and
furthermore, CD34þ cells from CB engraft much better in NOD/
SCID mice and few cells are required. We used Raji cells,
because homogenous expandable population of these cells
enabled to reproduce an acute lymphoblastic leukemia
model with reliable and constant proliferation and mortality
characteristics. As a note, in our hand primary leukemia cells do
not engraft readily in animals and were not usable for defining
an effect of MegaFasL (data not shown). As shown in Figure 3a,
all mice (five out of five; 100%) that received the untreated HPC/
Raji cell mixture developed paresis within 5 weeks post-
transplantation, whereas only two out of eight mice (25%)
given the cell mixture treated with MegaFasL became paretic
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Figure 2 In vitro functionality and in vivo repopulating capacity of HPC are not affected by MegaFasL treatment. CD34þ cells from mPB or CB
were incubated in medium with or without MegaFasL, then washed and plated on: (a) methocult medium for CFU assay, and (b) myelocult
medium for long-term culture-initiating cell (LTC-IC) assay. CFU and LTC-IC data are shown as mean±s.d. of five and three independent
experiments, respectively. BFU-E: burst forming units (erythroid colonies); CFU-G/M: granulocyte/macrophage colonies; and CFU-Mix are multi-
lineage colonies. (c) Transplanted immediately (pre-incubation) into irradiated NOD/SCID mice or incubated for 5 h, with or without MegaFasL
(post-incub) before transplantation into mice. Mice BM cells were analyzed by FACS for the presence of human (CD45þ ) cells. Data are from three
independent experiments and each point represents the percentage of human CD45þ cells present in the BM of one mouse. The blank squares
represent the percentage of human CD45þ cells present in the BM of mice engrafted with mPB, whereas filled circles represent the percentage of
human CD45þ cells present in the BM of mice engrafted with CB. (d) To demonstrate the presence of HPC in the BM of mice 6 weeks after
transplantation, flushed BM cells were plated on methylcellulose for a CFU assay. Results are from five mice (pre-incubation, post-incubation with
0 and 50 ng/ml MegaFasL) or four mice (post-incubation with 200 ng/ml MegaFasL) from three independent experiments. Lineage-specific colony
numbers were not statistically significant between each condition. Bone marrow cells from a mouse non-injected with human CD34þ cells and
similarly analyzed generated no colonies. BFU-E, CFU-G/M and CFU-Mix are as in (a).
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over a 40-day examination period. There was a significant
survival benefit in the MegaFasL-treated group compared with
the control group (log-rank test, Po0.001). In addition,
MegaFasL treatment had no significant effect on the repopulat-
ing function of HPC in mice injected with CD34þ /Raji cell
mixture (Supplementary Table 3). Importantly, no signs of
toxicity was observed in mice (n¼ 6) that received cell mixture
treated with MegaFasL for 6 weeks, no premature death
occurred in the treated group and the corresponding histo-
pathology of liver, spleen, lung, gut, kidney and inguinal lymph
nodes in this group was no different from untreated animals.
This observation does not support the hypothesis that insoluble
aggregates of MegaFasL remaining on the surface of treated cells
cause organ damage in the recipient. FACS analysis on BM
flushes from all six surviving mice injected with CD34þ /Raji
cell mixture treated with MegaFasL showed human hematopoi-
esis with cells bearing specific human markers for erythrocytes,
myeloid cells, B-lymphocytes and progenitor cells in propor-
tions very similar to those in mice injected with CD34þ cell
alone (Table 1 and Supplementary Table 3). In accordance with
this, CFU analyses performed on four of six BM flushes from the
surviving mice showed similar numbers of burst forming units-
erythroid colonies (P¼ 0.73, analysis of variance) and CFU-G/M
(P¼ 0.55, analysis of variance) colonies when compared with
analyses performed on CD34þ cell injected mice. Finally, FACS
analyses of the CFUs confirmed the presence of human
erythrocytes (five of six mice) and G/M (six out of six mice) in
the cells flushed from the BM of mice injected with an HPC/Raji
cell mixture treated with MegaFasL.
Raji tumor cells express CD19, so it could not be excluded from
the above that a fraction of the CD19þ cells were Raji cells
remaining in the BM after MegaFasL treatment. We performed two
types of experiments to address this point. First, we observed that
Raji cells, but not primary B cells, grow extensively and develop
large colonies upon plating on CFU medium. Application of this
procedure to BM flushes from four paretic mice showed 74±21%
(±s.e.m.) of CD19þ cells with the Raji phenotype, whereas
similar analysis on BM flushes from four available non-paretic
mice injected with a HPC/Raji cell mixture treated with MegaFasL
had 2±0.35% (±s.e.m.) of CD19þ cells. Second, t(8;14)
(q24;q32) Raji cell-specific DNA fragments were amplified by
PCR from BM from two available specimens from recipients of an
untreated cell mixture, whereas none of the six available recipients
of a MegaFasL-treated cell mixture had such fragment amplified
(Figure 3b). These data demonstrate that MegaFasL reduced tumor
burden within animals to undetectable levels by PCR assay, and
significantly delays the development of paresis at concentrations
that do not impair the potential of HPC to engraft, persist and
differentiate in vivo into the expected hematopoietic lineages.
The long-term in vivo tumor-preventing effect of MegaFasL on
Raji tumor cells was subsequently tested in similar animals.
Tumor development in 22 control animals led to a median
survival of 30 days (95% CI 24–46). In contrast, NOD/SCID
mice that received Raji cells treated with MegaFasL at 50 ng/ml
(n¼ 9) and 200 ng/ml (n¼ 11), survived significantly longer (log-
rank test Po0.0001 for both groups) and their median survival
times were not reached at day 120 (Figure 3c). Survivals of
animals injected with Raji cells treated with 50 and 200 ng/ml of
MegaFasL were similar (P¼ 0.9 between the two groups). This
observation confirmed the significant tumor preventive activity
at long term of MegaFasL when incubated in vitro before
transplantation.
*** p < 0.0001, vs control
***
P= 0.71***
Figure 3 MegaFasL treatment of a cell mixture prevents in-vivo tumor development at concentrations that do not affect the hematopoietic
repopulating function of CD34þ cells. (a) Mice (n¼ 8) injected with a CD34þCB/Raji cell mixture treated with MegaFasL survived significantly
longer than mice (n¼ 5) injected with an untreated CD34þCB/Raji cell mixture. Data are expressed as the proportion of surviving mice against
time. (b) PCR amplification of t(8;14)(q24;q32) present in Burkitt’s lymphoma (7.6 kb) in DNA extracted from BM cells from: mice that received
untreated cell mixture (lanes 1–2); mice that received a cell mixture treated with MegaFasL (lanes 3–8); pure Raji cell preparation (100) and from
Raji cells diluted up to a 100-fold (101–102) with NOD/SCID mouse BM cells. Negative controls for PCR include DNA extracted from a non-
injected NOD/SCID mouse (lane 9) and buffer (lane 10). DNA fragment of human-specific b-globin gene (268 bp) was used as control for PCR
amplifications of human DNA. M, markers. Top: DNA ladder mix. Bottom: 50-bp DNA ladder. (c) A total of 11 animals given 200 ng/ml MegaFasL-
treated Raji cells and 9 animals given 50 ng/ml MegaFasL-treated Raji cells survived significantly longer than 22 animals (controls) receiving
untreated Raji cells (log rank test, Po0.0001).
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Discussion
In the present study, we exploit the concept of using MegaFasL
as an ex-vivo purging agent in a model of ASCT following
myeloablative high-dose chemotherapy. We showed that
MegaFasL could safely eradicate leukemia and lymphoma cells
without altering the function of HPC, regardless of their source.
We used notably an in-vivo repopulating hematopoietic cell
assay, where BM of animals have been analyzed 6 weeks after
transplantation, enabling the detection of primitive HPC. The
resistance to MegaFasL-induced apoptosis observed in
CD34þCD38low cells from mPB, BM or CB is consistent with
previous reports indicating HPC resistance to Fas-inducing
apoptosis when using other Fas agonists. This resistance of
HPC is most likely to be due to low level of cell surface Fas
expression and to overexpression of anti-apoptotic proteins such
as cFLIP21 and caspase-8L.22 In contrast, human hematological
malignant cells were highly sensitive to MegaFasL treatment,
with AML, MM and lymphoma cells being the most sensitive.
MegaFasL sensitivity level correlates with that of Fas expression
on the cell population. The high sensisitivity of most primary
hematopoietic malignant cells towards MegaFasL could be
explained by its potent killing effects compared with other Fas
agonists. Indeed, we previously demonstrated and confirmed
here that MegaFasL is able to induce apoptosis in primary
malignant cells and cancer cell lines which are resistant to other
Fas agonists, including sFasL, sFasL M2 and CH11.18 In an
animal model of human transplantation, we showed that
MegaFasL treatment of a mixed cell population of human HPC
and tumor cells, before transplantation, clearly eliminated tumor
cells, thus preventing tumor development at long term. This
finding highlights that MegaFasL can selectively eliminate tumor
cells without damping in the presence of a large amount of
CD34þ cells, and the potential use of MegaFasL as an ex-vivo
purging agent in ASCT, where the presence of residual tumor
cells in the infused hematopoietic cells, often evidenced by gene
marking, could contribute to relapse after transplantation in
follicular lymphoma,1 AML,3 CML4 and MM.2 The interest of
purging the autograft is also based on findings from studies
reporting that patients infused with autologous hematopoietic
cells, free of contaminating cancer cells as assessed by PCR,
have a longer disease-free period than those patients infused
with autologous cells that are positive for cancer cells by PCR
assay.31,32 Importantly, the ex-vivo use of MegaFasL allows to
circumvent any potential in-vivo toxicity issues of Fas agonists in
humans, because stem cell transplants would be treated with
MegaFasL, then washed to remove MegaFasL before re-infusion
into a patient, ensuring the safety of the procedure. Indeed,
MegaFasL is not detectable in the cell supernatant after three
centrifugal washes (Supplementary Figure 5). Furthermore,
MegaFasL induces cell death via death receptor signaling
pathways, a mechanism mostly independent of those utilized
by classical chemotherapeutic agents. This could be advanta-
geous in an ASCT setting, where residual tumor cells within the
HPC graft could be resistant to conventional chemotherapy
treatment due to repeated administration before cell harvesting.
In summary, the data presented here validate the principle of
using MegaFasL as an ex-vivo purging agent in HPC transplanta-
tion and demonstrate its potential that could be evaluated in a
clinical setting. The simplicity of purging an autograft with
MegaFasL, its strong apoptotic effect on various hematological
disorders, and the absence of evident HPC toxicity, underline
the advantages of MegaFasL. The use of MegaFasL as an ex-vivo
purging agent in ASCT may likely provide a rapid and simple,
and safe method for removing contaminating cancer cells from
HPC preparations. Future trials will evaluate the benefit of this
strategy in ASCT in humans.
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Table 1 Lineage-specific human hematopoietic cells in BM from CD34+ CB cell-transplanted NOD/SCID mice
Hematopoietic lineage FACS analysis of BM cells (%)
Prior-incubation Post-incubation MegaFasL (ng/ml)
0 50 200
Glycophorin Aþ (erythroid) cellsa 0.4±0.4 (n¼ 5)z 0.6±0.4 (n¼5) 1.0±1.2 (n¼ 5) 0.2±0.3 (n¼5)
CD45þ (leukocytes) cellsa 17.5±17.4 (n¼5) 23.4±9.7 (n¼5) 22.5±20.2 (n¼ 5) 10.7±10.3 (n¼5)
CD45þCD33þ (myeloid)/CD45þ cellsb 7.5±1.8 (n¼ 3) 6.4±2.0 (n¼3) 10.0±5.0 (n¼ 3) 9.4±3.4 (n¼3)
CD45þCD14þ (monocytes)/CD45þ cellsb 4.3±0.9 (n¼ 2) 2.5±0.8 (n¼2) 4.2±1.71 (n¼ 2) 3.6±0.4 (n¼2)
CD45þCD19þ (B lineage)/CD45þ cellsb 78.8±3.2 (n¼ 3) 83.2±4.7 (n¼3) 76.2±7.6 (n¼ 3) 74.2±7.7 (n¼3)
CD45þCD34þ (progenitors )/CD45þ cellsb 25.1±5.9 (n¼ 3) 21.2±5.7 (n¼3) 23.7±4 (n¼ 3) 21.6±3.8 (n¼3)
Abbreviations: BM, bone marrow; CB, cord blood; FACS, fluorescence-activated cell sorting.
aPercentages of positive cells flushed from the BM using FACS and anti-human erythroid cells (Glycophorin A) and leukocytes (CD45) antibodies.
bPercentages of human leukocyte subsets among CD45+ human leukocytes, evidenced using antibodies against human myeloid (CD33+),
monocytic (CD14+), lymphoid B (CD19+) and progenitor (CD34+) cells. All tests were run in parallel with isotypic control antibodies to account for
any non-specific binding staining. Erythroid cell-, leukocyte- and lineage-specific cell-percentages were not significantly different between each
condition. FACS plots of a representative analysis are shown in Supplementary Figure 4.
zNumber of animals.
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